The potential of biomarkers of fibrosis in chronic lung allograft dysfunction.

Eline A van der Ploeg, Barbro N Melgert, Janette K Burgess, C Tji Gan

Transplantation reviews (Orlando, Fla.) 2021 Jul

filter terms:

Chronic lung allograft dysfunction (CLAD) is the major long-term cause of morbidity and mortality after lung transplantation. Both bronchiolitis obliterans syndrome and restrictive lung allograft syndrome, two main types of CLAD, lead to fibrosis in either the small airways or alveoli and pleura. Pathological pathways in CLAD and other types of fibrosis, for example idiopathic pulmonary fibrosis, are assumed to overlap and therefore fibrosis biomarkers could aid in the early detection of CLAD. These biomarkers could help to differentiate between different phenotypes of CLAD and could, in comparison to biomarkers of inflammation, possibly distinguish an infectious event from CLAD when a decline in lung function is present. This review gives an overview of known CLAD specific biomarkers, describes new promising fibrosis biomarkers currently investigated in other types of fibrosis, and discusses the possible use of these fibrosis biomarkers for CLAD. Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Citation

Eline A van der Ploeg, Barbro N Melgert, Janette K Burgess, C Tji Gan. The potential of biomarkers of fibrosis in chronic lung allograft dysfunction. Transplantation reviews (Orlando, Fla.). 2021 Jul;35(3):100626